Brind.

U.S. Phase 3 Study 15302 involving Kolon TissueGene failed, with the FDA being aware of the situation.

1 report, 1 independent Updated Jul 1

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

FDA Kolon TissueGene

Keep exploring

The entities involved

FDA
- Legislation requires the FDA to study formula metals, while Donald Trump endorses a candidate focused on economic growth.02:09
- FDA reviewed an NDA and entered a clinical study agreement for a babesiosis trial involving 60 Degrees Pharmaceuticals.Wed 23:20
Kolon TissueGene
Nothing else this week.

Coverage

Newest first; wire copies grouped

Jul 1edaily.co.krKolon TissueGene Escapes Fourth Limit-Down; Peptron Jumps After Hours[K-Bio Pulse]